Wockhardt to launch Cefprozil in the US

New Delhi, June 20 (UNI) Wockhardt Ltd today said it has received the US Federal and Drug Administration (FDA) approval for launching its antibiotic 'Cefprozil' in the US market.

The company will launch Cefprozil, the generic version of brand Cefzil, in the strengths of 250 and 500 mg to be sold by Bristol Myers Squibb.

The tablet, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections.

''Cefprozil will be a good addition to our range in the US, with a market potential of around 51 million dollars,'' said company Chairman Habil Khorakiwala.

''This is our eighth approval in just four months which will significantly contribute to our growing visibility in the US market,'' he added.

UNI